WELL Health
Trending >

Buy Medicure on weakness, says M Partners


MedicureAhead of the company’s Q1, 2017 results, M Partners analyst Steven Salz thinks Medicure (Medicure Stock Quote, Chart, News: TSX:MPH) is undervalued.

On Wednesday, Medicure will report its first quarter results. Salz thinks the company will post fully diluted earnings of $0.09 and EBITDA of $4.0-million on revenue of $12.3-million. The street consensus has the company earning $0.04 and posting EBITDA of $5.4-million on a topline of $12.2-million.

Salz says he thinks the recent weakness in the stock is related to its Apicore dealings.

“We believe recent share price weakness reflects market doubt whether MPH will exercise the remainder of its Apicore option,” he says. “The share price is currently trading at levels not seen since before the announcement of the initial acquisition for 64% majority interest in Apicore last November. Based on our estimates, the remaining 40% interest in Apicore on a fully diluted basis represents ~$0.60/share, substantially below the current valuation implication from the recent selloff. We remind investors that Medicure has until July 3rd, 2017 to exercise the company’s in the money option for the remaining issued shares of Apicore.”

In a research update to clients today, Salz maintained his “Buy” rating and one-year price target of $10.00 on Medicure, implying a return of 37 per cent at the time of publication.

Salz thinks Medicure will post EBITDA of $20.1-million on revenue of $65.7-million in fiscal 2017.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

About The Author /

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.
insta twitter facebook


Leave a Reply